Printify
Empowerment Journal (Purple Galaxy Art)
Empowerment Journal (Purple Galaxy Art)
Couldn't load pickup availability
Elevate your journaling experience with a purpose. This beautifully designed purple matte hardcover journal offers 150 lined pages (75 sheets) for all your thoughts, plans, and ideas. Sized at 5.75"x8", it’s perfect for on-the-go note-taking or personal reflection. With a durable casewrap binding and a sleek matte finish, this journal combines style with substance.
But this journal is more than just a space for your writing—40% of all revenue from every purchase goes directly to fund pancreatic cancer research. When you buy this journal, you’re not only investing in yourself, but also in the fight to find a cure. Let your words make a difference today.
- Full wraparound print
- Matte finish for a polished look
- 150 lined pages (75 sheets)
- Casewrap binding for durability
Note: A small 0.5"x0.5" barcode will be printed on the back cover.
Share






Recent News
View all-
Phase 1/2 Trial Launches for Innovative Pancrea...
UCSF researchers begin testing novel TCR-T cell therapy targeting KRAS mutations in advanced pancreatic cancer. A new clinical trial at UCSF has opened to test a first-of-its-kind immunotherapy for advanced...
Phase 1/2 Trial Launches for Innovative Pancrea...
UCSF researchers begin testing novel TCR-T cell therapy targeting KRAS mutations in advanced pancreatic cancer. A new clinical trial at UCSF has opened to test a first-of-its-kind immunotherapy for advanced...
-
FDA Approves NALIRIFOX as First-Line Treatment ...
New frontline treatment offers hope with improved survival outcomes for advanced PDAC patients The U.S. Food and Drug Administration (FDA) has officially approved NALIRIFOX, a new frontline therapy for patients with metastatic...
FDA Approves NALIRIFOX as First-Line Treatment ...
New frontline treatment offers hope with improved survival outcomes for advanced PDAC patients The U.S. Food and Drug Administration (FDA) has officially approved NALIRIFOX, a new frontline therapy for patients with metastatic...
-
Immunotherapy for Pancreatic Ductal Adenocarcin...
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, with a 5-year survival rate under 10%. Standard treatments like surgery and chemotherapy often fail because the cancer usually comes...
Immunotherapy for Pancreatic Ductal Adenocarcin...
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, with a 5-year survival rate under 10%. Standard treatments like surgery and chemotherapy often fail because the cancer usually comes...